2019-03-06T12:43:25-06:00 2018-06-30 910189318 MOSS ADAMS LLP 805 SW BROADWAY STE 1200 PORTLAND OR 97205 990 2017-07-01 910961784 SEATTLE BIOMEDICAL RESEARCH INSTITUTE SEAT 2062567200 307 WESTLAKE AVENUE NORTH NO 500 SEATTLE WA 981095219 DAVID KEOGH PRESIDENT 2062567200 2019-02-14 1 WENDY CAMPOS P00448102 5032421447 2019-02-07 12.129.7.100 2019-02-14 10:34:45 PS P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 D294BCF825AD6123C8D8C79B00469E80119B4775 2017 2019-02-21 02:37:17Z CENTER FOR INFECTIOUS DISEASE RESEARCH DAVID KEOGH 307 WESTLAKE AVENUE NORTH NO 500 SEATTLE WA 981095219 37266123 0 X WWW.CIDRESEARCH.ORG X 1976 WA TO ELIMINATE THE WORLD'S MOST DEVASTATING INFECTIOUS DISEASES. 18 17 244 20 0 244772 32425712 30598366 139168 325859 596958 1222458 -22250 -1842850 33139588 30303833 0 0 0 0 16385504 16531991 0 0 247822 20597256 17685952 36982760 34217943 -3843172 -3914110 37343646 33632197 7465759 7668420 29877887 25963777 X WE CONDUCT FUNDAMENTAL INFECTIOUS DISEASE RESEARCH TO GENERATE CRITICAL NEW KNOWLEDGE ABOUT PATHOGENS AND THEIR INTERACTIONS WITH SEE SCHEDULE O FOR CONTINUATIONHUMANS TO ENABLE THE DISCOVERY AND DEVELOPMENT OF NOVEL INTERVENTIONS, RATIONAL VACCINES, THERAPEUTIC TARGETS, DRUGS AND DIAGNOSTICS. THESE DISEASES INCLUDE, BUT ARE NOT LIMITED TO, TUBERCULOSIS, MALARIA, AND HIV.WE ARE ALSO ENGAGED IN TRAINING THE NEXT GENERATION OF SCIENTISTS WHO WILL PERFORM SCIENTIFIC RESEARCH AND ADD CLINICAL CAPACITY THROUGHOUT THE WORLD. 0 0 31472191 325859 WE CONDUCT FUNDAMENTAL INFECTIOUS DISEASE RESEARCH TO GENERATE CRITICAL NEW KNOWLEDGE ABOUT PATHOGENS AND THEIR INTERACTIONS WITH HUMANS TO ENABLE THE DISCOVERY AND DEVELOPMENT OF NOVEL INTERVENTIONS, RATIONAL VACCINES, THERAPEUTIC TARGETS, DRUGS AND DIAGNOSTICS. THESE DISEASES INCLUDE, BUT ARE NOT LIMITED TO, TUBERCULOSIS, MALARIA, AND HIV. WE ARE ALSO ENGAGED IN TRAINING THE NEXT GENERATION OF SCIENTISTS WHO WILL PERFORM SCIENTIFIC RESEARCH AND ADD CLINICAL CAPACITY THROUGHOUT THE WORLD.SEE SCHEDULE O FOR CONTINUATIONACCOMPLISHMENTS INCLUDE: -DISCOVERY OF RNA EDITING, WHICH PROVIDES A POTENTIAL BASIS FOR DRUG TREATMENTS FOR THREE MAJOR PARASITIC DISEASES.-IDENTIFICATION OF TWO HIV1 ENVELOPE ANTIGENS THAT ELICITED BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV WHEN INTRODUCED AS A TRIAL VACCINE IN PRIMATES.-GENETICALLY ENGINEERED THE MALARIA PARASITE P. FALCIPARUM BY THE PRECISE REMOVAL OF SPECIFIC GENES, CREATING A STRAIN THAT INFECTS HUMANS AND IS WELL TOLERATED BUT CANNOT CAUSE MALARIA, THUS MAKING IT A NOVEL NEW VACCINE CANDIDATE. 49303 BIOQUEST: THE PRIMARY GOAL OF THE INSTITUTE'S SCIENCE OUTREACH PROGRAM, BIOQUEST, IS TO PROVIDE A CURRICULUM-RELEVANT, CAREER-INSPIRING, TECHNOLOGY-RICH SCIENCE EDUCATION PROGRAM WITHIN THE CONTEXT OF INFECTIOUS DISEASE RESEARCH TO HIGH SCHOOL STUDENTS, TEACHERS, AND THE GENERAL PUBLIC. WE ARE THE ONLY ORGANIZATION IN THE NATION TO OFFER A 32-PERSON TEACHING LAB, WITHIN THE FOOTPRINT OF AN INFECTIOUS DISEASE RESEARCH INSTITUTE. 31521494 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 56 0 1 244 1 1 1 0 0 0 0 0 0 0 0 0 X 18 17 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 WA X X MISTIE FAIN 4157444352 307 WESTLAKE AVE N 500 SEATTLE WA 981095219 IRWIN GOVERMAN CHAIR 3.00 X X 0 0 0 KEVIN KELLY VICE CHAIR 3.00 X X 0 0 0 GREGG BLODGETT TREASURER 3.00 X X 0 0 0 STEVEN CLIFFORD SECRETARY 3.00 X X 0 0 0 ROSEMARY ARAGON TRUSTEE 3.00 X 0 0 0 MARK ASHIDA TRUSTEE 3.00 X 0 0 0 PATRICE AULD TRUSTEE 3.00 X 0 0 0 DAVID GOESLING TRUSTEE 3.00 X 0 0 0 ALAN LEVY TRUSTEE 3.00 X 0 0 0 TREVER MOODY TRUSTEE 3.00 X 0 0 0 BRIAN OLSAVSKY TRUSTEE 3.00 X 0 0 0 TJ PETRIZZO TRUSTEE 3.00 X 0 0 0 MARK MATHEWSON TRUSTEE 3.00 X 0 0 0 BRIAN SCHWARTZ TRUSTEE 3.00 X 0 0 0 DAVID STEWART TRUSTEE 3.00 X 0 0 0 PERRY ATKINS TRUSTEE 3.00 X 0 0 0 ROB THOMAS TRUSTEE 3.00 X 0 0 0 KEN STUART TRUSTEE/FOUNDER 40.00 X X 370918 0 30560 JOHN AITCHISON PRESIDENT 40.00 X 245697 0 34740 STEFAN KAPPE VP STRATEGIC DEVELOPMENT 40.00 X 261243 0 30184 DAVID KEOGH CHIEF OPERATING OFFICER 40.00 X 164463 0 21059 DAVID SHERMAN ASSOCIATE DIRECTOR 40.00 X 183862 0 26001 ALAN ADEREM PRESIDENT EMERITUS 40.00 X 363309 0 39676 PETER MYLER PROFESSOR 40.00 X 172434 0 27108 RONALD HOOD SENIOR DIREC IT 40.00 X 192888 0 19828 CHRISTOPHER GRUNDER ASSOCIATE PROFESSOR 40.00 X 167007 0 11406 KENT IRWIN SR. DIR OPERATIONS/FACIL 40.00 X 156538 0 15546 KEVIN URDAHL PROFESSOR MD 40.00 X 151589 0 15614 JOSEPH SMITH PROFESSOR 40.00 X 155357 0 23154 2585305 0 294876 25 0 1 0 UNIVERSITY OF WASHINGTON GRANTS & CONTRA 12455 COLLECTIONS DR CHICAGO IL 60693 RESEARCH 2192016 YECURIS CORPORATION PO BOX 4645 TUALATIN OR 97062 RESEARCH 1613900 BERYLLIUM DISCOVERY CORP 3 PRESTON CT BEDFORD MA 01730 RESEARCH 1355035 INSTITUTE FOR SYSTEMS BIOLOGY 401 TERRY AVE N SEATTLE WA 98109 RESEARCH 1191911 FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE N SEATTLE WA 98109 RESEARCH 398626 21 25495531 5102835 30598366 RESEARCH SUPPORT 541900 325859 325859 325859 383978 383978 928860 2771710 -1842850 -1842850 -1842850 5024334 4726 4190580 0 833754 4726 838480 838480 30303833 325859 0 -620392 2171072 1513858 657214 10629358 9665128 763033 201197 1322986 1199617 100271 23098 318888 263711 55659 -482 2089687 1824984 231857 32846 116017 116017 74915 74915 25334 25334 741016 573327 165334 2355 717 665 47 5 241907 203271 37751 885 554875 502483 45192 7200 3193203 2759712 393650 39841 217616 198323 16105 3188 111231 97370 11076 2785 1139523 1084471 48700 6352 213435 42966 170469 SUBCONTRACTS 6507284 6506772 465 47 RESEARCH SUPPLIES 3708877 3706569 2096 212 OTHER EXPENSES 578220 1112572 -463005 -71347 LAB/CLINICAL/TECH SVS 261782 265695 -3553 -360 34217943 31521494 2448627 247822 1100 1100 3030476 4077646 7695580 6576336 52894 53999 42450 47949 68767 41609 423118 320465 23714713 18569855 5548640 5144858 20480621 17368235 37343646 33632197 3170412 4294277 2630867 1685487 1664480 1688656 7465759 7668420 X 29742719 24969982 135168 993795 29877887 25963777 37343646 33632197 -3914110 0 X 0 1 X 1 1 1 X UNIVERSITY OF WASHINGTON MEDICAL CENTER SEATTLE WA OREGON HEALTH & SCIENCE UNIVERSITY PORTLAND OR 11631063 8231192 3399871 11230925 9537119 1693806 852725 801544 51181 5144858 DEFERRED RENT LIABILITY 1683706 SECURITY DEPOSITS - SUBTENANTS 4950 1688656 X 33078134 0 33078134 -2774301 -2774301 30303833 36992244 2774301 2774301 34217943 0 34217943 PART X, LINE 2: THE CENTER FOLLOWS THE PROVISIONS OF AUTHORITATIVE GUIDANCE RELATING TO ACCOUNTING FOR UNCERTAIN TAX POSITIONS. THE AGENCY RECOGNIZES THE TAX BENEFIT FROM UNCERTAIN TAX POSITIONS ONLY IF IT IS MORE LIKELY THAN NOT THAT THE TAX POSITIONS WILL BE SUSTAINED ON EXAMINATION BY THE TAX AUTHORITIES, BASED ON THE TECHNICAL MERITS OF THE POSITION. THE TAX BENEFIT IS MEASURED BASED ON THE LARGEST BENEFIT THAT HAS A GREATER THAN 50% LIKELIHOOD OF BEING REALIZED UPON ULTIMATE SETTLEMENT. THE CENTER RECOGNIZES INTEREST AND PENALTIES RELATED TO INCOME TAX MATTERS IN INCOME TAX EXPENSE. AS OF JUNE 30, 2018 AND 2017, THE CENTER HAD NO UNCERTAIN TAX POSITIONS REQUIRING ACCRUAL. PART XI, LINE 4B - OTHER ADJUSTMENTS: RENTAL EXPENSES -2,771,710. FOREIGN EXCHANGE LOSS -2,591. PART XII, LINE 2D - OTHER ADJUSTMENTS: RENTAL EXPENSES 2,771,710. FOREIGN EXCHANGE LOSS 2,591. X 0 1 X X X 0 0 0 0 0 0 0 0 0 KEN STUART TRUSTEE/FOUNDER 370918 0 0 0 0 0 29738 0 822 0 401478 0 0 0 JOHN AITCHISON PRESIDENT 245697 0 0 0 0 0 24425 0 10315 0 280437 0 0 0 STEFAN KAPPE VP STRATEGIC DEVELOPMENT 261243 0 0 0 0 0 24687 0 5497 0 291427 0 0 0 DAVID KEOGH CHIEF OPERATING OFFICER 164463 0 0 0 0 0 16146 0 4913 0 185522 0 0 0 DAVID SHERMAN ASSOCIATE DIRECTOR 183862 0 0 0 0 0 18188 0 7813 0 209863 0 0 0 ALAN ADEREM PRESIDENT EMERITUS 363309 0 0 0 0 0 28146 0 11530 0 402985 0 0 0 PETER MYLER PROFESSOR 172434 0 0 0 0 0 16978 0 10130 0 199542 0 0 0 RONALD HOOD SENIOR DIREC IT 192888 0 0 0 0 0 19077 0 751 0 212716 0 0 0 CHRISTOPHER GRUNDER ASSOCIATE PROFESSOR 167007 0 0 0 0 0 10850 0 556 0 178413 0 0 0 KENT IRWIN SR. DIR OPERATIONS/FACIL 156538 0 0 0 0 0 15233 0 313 0 172084 0 0 0 KEVIN URDAHL PROFESSOR MD 151589 0 0 0 0 0 15058 0 556 0 167203 0 0 0 JOSEPH SMITH PROFESSOR 155357 0 0 0 0 0 15431 0 7723 0 178511 0 0 0 PART I, LINE 1A FIRST CLASS TRAVEL IS PERMITTED IF ALLOWABLE UNDER AN AWARD AND/OR THE DIFFERENTIAL IN PRICE IS PAID FOR OUT OF NON-GRANT FUNDS. STEFAN KAPPE PART V PART V X 80000 47949 0 1 1 47949 PART II STEFAN KAPPE IS AN OFFICER REPORTED ON PART VII EMPLOYED AS VP STRATEGIC DEVELOPMENT. THE LOAN IS RETENTION RELATED AND NOT RESTRICTED TO A SPECIFIC USE. FORM 990, PART VI, SECTION A, LINE 1 THE BOARD CAN DELEGATE AUTHORITY TO THE EXECUTIVE COMMITTEE OR OTHER SUBCOMMITTEES (E.G. FINANCE) HOWEVER MOST DECISIONS COME TO THE FULL BOARD FOR ACTION AFTER VETTING AT THE COMMITTEE LEVEL. THERE ARE NO MATERIAL DIFFERENCES AMONG MEMBERS OF THE BOARD. THERE ARE TWO NON-INDEPENDANT VOTING MEMBERS OF THE BOARD WHO ARE TRUSTEES. FORM 990, PART VI, SECTION B, LINE 11B THE RETURN WILL BE REVIEWED IN DETAIL BY THE CONTROLLER. IN ADDITION, THE 990 WILL BE PRESENTED TO THE BOARD OF DIRECTORS. ANY PERTINENT RESPONSES WILL BE ADDRESSED AND RESOLVED BEFORE THE FINAL TAX RETURN IS FILED. FORM 990, PART VI, SECTION B, LINE 12C EACH TRUSTEE (AND ALL KEY EMPLOYEES) AND MEMBERS OF A COMMITTEE WITH BOARD DELEGATED POWERS SHALL ANNUALLY SIGN A STATEMENT WHICH AFFIRMS THAT SUCH PERSON HAS RECIEVED A COPY OF THE CONFLICT OF INTEREST POLICY, HAS READ AND UNDERSTANDS THE POLICY, AND AGREES TO COMPLY WITH THE POLICY. IF ANY KNOWN CONFLICTS ARISE, THEY ARE SENT TO THE EXECUTIVE COMMITTEE FOR RESOLUTION. A FOLLOWUP TO THE LEADERSHIP TEAM THEN OCCURS, IF NEEDED. PROCEDURE: 1. DUTY TO DISCLOSE: IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE EXISTANCE AND NATURE OF HIS/HER FINANCIAL INTEREST TO THE EXECUTIVE COMMITTEE OF THE BOARD OF TRUSTEES PRIOR TO CONSIDERATION OF THE PROPOSED TRANSACTION OR ARRANGEMENT AND MUST NOT ENTER INTO ANY ARRANGEMENT WHERE THERE IS AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST WITHOUT EXECUTIVE COMMITTEE APPROVAL. 2. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: AFTER DISCLOSURE OF THE FINANCIAL INTEREST, THE INTERESTED PERSON SHALL RECUSE HIMSELF/HERSELF WHILE THE FINANCIAL INTEREST IS DISCUSSED AND VOTED UPON. THE EXECUTIVE COMMITTEE SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. 3. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. THE EXECUTIVE COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. B. AFTER EXERCISING DUE DILLIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER SEATTLE BIOMED CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. C. IF A MORE ADVANTAGOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED MEMBERS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN THE INSTITUTE'S BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO THE INSTITUTE AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. 4. VIOLATIONS OF THE CONFLICTS OF INTEREST POLICY: A. IF THE BOARD, A COMMITTEE, THE INSTITUTE'S STAFF OR A TRUSTEE HAS REASONABLE CAUSE TO BELIEVE THAT A TRUSTEE OR A COMMITTEE MEMBER HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OF THE BASIS FOR SUCH BELIEF AND AFFORD THE MEMBER THE OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF THE MEMBER AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE EXECUTIVE BOARD DETERMINES THAT THE MEMBER HAS, IN FACT, FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION PLANNING AND REVIEW TAKES PLACE ANNUALLY. HUMAN RESOURCES PROVIDES MARKET DATA FOR EACH POSITION IN THE INSTITUTE. FOR SENIOR LEADERSHIP POSITIONS, SPECIFICALLY KEY EMPLOYEES, AN OUTSIDE COMPENSATION CONSULTANT BENCHMARKS THESE POSITIONS AND PROVIDES DATA AND ANALYSIS, WHICH ALLOWS THE ORGANIZATION'S HUMAN RESOURCE DEPARTMENT TO ESTABLISH A PAY RANGE FOR EACH OF THESE ROLES AT OUR INSTITUTE. THE HUMAN RESOURCE DEPARTMENT ALSO GATHERS INDUSTRY-SPECIFIC INFORMATION FROM OUR PEERS TO VALIDATE THE SURVEY INFORMATION AND TO ENSURE THAT WE REMAIN COMPETITIVE WITH OUR COMPENSATION. THIS INFORMATION IS SOMETIMES GATHERED FROM LOCAL PEER ORGANIZATIONS IN OUR INDUSTRY AND/OR FROM PEER ORGANIZATIONS WHO ARE PART OF THE ASSOCIATION OF INDEPENDENT RESEARCH INSTITUTES (AIRI). THE MOST RECENT COMPENSATION REVIEW OF SENIOR POSITIONS TOOK PLACE IN APRIL 2017. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.